The emergence of Vancomycin resistant enterococci (VRE) has posed serious threats to the community because they exhibit multiple drug resistance, thus limiting the therapeutic options for the clinicians. As Vancomycin resistant enterococci (VRE) also have ampicillin resistance and high level aminoglycoside resistance, they are the most difcult to treat. The therapeutic options are limited by elimination of the synergy between aminoglycoside and the beta lactum drugs which is the treatment of choice for enterococcal infections which is of great concern. More antibiotic resistance makes these pathogens excellent survivors in hospital environment and cause nosocomial infections. Atotal of 142 enterococcal isolates from various clinical samples were identied to their species level and subjected to antimicrobial susceptibility testing to various antibiotics. Initial screening for Vancomycin resistance was done using the Vancomycin Screen Agar and the isolates showing resistance were subjected to Vancomycin and Teicoplanin MIC and later these isolates showing resistance were conrmed by genotypic methods for Vancomycin resistant genes.Total VRE isolates as per Vancomycin MIC value were 19 and the prevalence rate was 13.3% (19/142).In PCR assay, a total of 16 isolates including 13 E.faecium and 3 E.faecalis were found to be of Van B genotype and the remaining 3 isolates including 2 E.faecium and 1 E.faecalis were found to be of Van A genotype. In this study, the prevalence of Vancomycin resistance in Enterococcal species is 13.3% as per vancomycin MIC by Micro broth dilution technique. The phenotypic detection of Vancomycin resistance by MIC of Vancomycin and Teicoplanin correlates with the genotypic method of detection of Vancomycin resistant genes (VanA, VanB).
Gram-negative bacilli may commonly produce aminoglycoside modifying enzymes. However, any one of these enzymes alone cannot confer resistance to all commonly used aminoglycosides because of their narrower substrate specificities(3,13).But ,the mechanism of resistance mediated by 16S rRNA methylases that methylates residue G1405 is the very high level of resistance to all parenterally formulated aminoglycosides (MIC>128ug/ml) commonly used (16). Screening for 16S rRNA methylase producing organisms has become an essential measure to be taken for epidemiological as well as diagnostic purposes when nosocomial spread of such bacteriae is suspected. Only by early identification of these resistant determinants (armA, rmtB and rmtC) by molecular methods can help us to design appropriate antibiotic and infection-control policies which are necessary to limit the nosocomial spread of these resistance organisms (2).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.